MISSISSAUGA, ON, May 19, 2021 /CNW/ - Nuvo Pharmaceuticals Inc.
(TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the
Company), a Canadian-focused healthcare company with global reach
and a diversified portfolio of commercial products, today announced
the appointment of Mary Ritchie to
its Board of Directors.
Mary Ritchie is the President and
Chief Executive Officer of Richford Holdings Ltd., an accounting
and investment advisory services firm based in Edmonton, Alberta. Ms. Ritchie has over
30 years of experience in both the public, private and
not-for-profit sectors and is a Fellow of CPA Alberta. She is
a member of the board of directors and audit committees of Alaris
Royalty Corp. (TSX), EnWave Corporation (TSXV) and Morien Resources
Inc. (TSXV). She has been a past director on a number of
boards, including the Canada Pension Plan Investment Board,
Industrial Alliance Insurance, Financial Services Inc. (TSX), iA
Financial Corporation Inc. (TSX), Axcan Pharma Inc. (TSX),
Isotechnika Inc. (TSX) and a past member of the RBC Global Asset
Management's independent oversight committee.
Jesse Ledger, President &
Chief Executive Officer of Miravo commented, "We are excited to
welcome Mary to our Board of Directors. Mary's past Director
engagements and Audit Committee roles with various public, private
and not-for-profit companies in Canada and Internationally, has provided her
with a wealth of experience across many different sectors,
including pharmaceuticals. This cross-sector experience and
knowledge makes her an excellent addition to our Board."
Ms. Ritchie was nominated to join the Board and subsequently
appointed during the proceedings of the Miravo Healthcare Annual
General Meeting of Shareholders convened on May 17, 2021.
About Miravo Healthcare
Miravo is a Canadian focused,
healthcare company with global reach and a diversified portfolio of
commercial products. The Company's products target several
therapeutic areas, including pain, allergy, neurology and
dermatology. The Company's strategy is to in-license and
acquire growth-oriented, complementary products for Canadian and
international markets. Miravo's head office is located in
Mississauga, Ontario, Canada, the
international operations are located in Dublin, Ireland and the Company's
manufacturing facility is located in Varennes, Québec, Canada. The
Varennes facility operates in a
Good Manufacturing Practices (GMP) environment respecting the U.S,
Canada and E.U. GMP regulations
and is regularly inspected by Health Canada and the U.S. Food and
Drug Administration. For additional information, please visit
View original content to download
SOURCE Nuvo Pharmaceuticals Inc.